Figure 2

Kinetics of changes in mRNA (a) and protein (b) levels of tenascin-C in the RPE-choroid complex obtained from a mouse CNV model (mean±s.e.m.; n=4 eyes per group). (a and b) Tenascin-C expression is significantly increased and peaked 3 days after laser photocoagulation. (c) Western blots of tenascin-C in the RPE-choroid complex of a mouse CNV model. The mouse monoclonal anti-tenascin-C clone 4F10TT antibody displayed 210 and 250 kDa isoforms of tenascin-C, and a similar trend. (d) Expression of tenascin-C mRNA normalized to GAPDH in hRPE cells stimulated with the indicated concentrations of transforming growth factor-β2 (TGF-β2) (mean±s.e.m.; n=4 per group). (e) ELISA of tenascin-C in the cell lysates and supernatants of hRPE cells stimulated with the indicated concentrations TGF-β2 (mean±s.e.m.; n=4 per group). (d, e) TGF-β2 significantly induces the expression of tenascin-C mRNA and protein, in a dose-dependent manner. (f) Western blot analysis of tenascin-C and β-actin in hRPE cells stimulated by the indicated concentrations of TGF-β2. The mouse monoclonal anti-tenascin-C clone 4F10TT antibody showed two isoforms of tenascin-C (210 and 300 kDa) and a similar trend. β-actin was used as the loading control. *P<0.05, **P<0.01, ANOVA/Dunnett’s test, compared to the control.